Valziflocept
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) [1].
Product Specifications
CAS Number
[1804910-11-9]
Product Name Alternative
BAX1810; TAK-752
UNSPSC
12352203
Target
Fc Receptor (FcR)
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/valziflocept.html
Purity
99.00
Solubility
10 mM in DMSO
Smiles
[Valziflocept]
Molecular Weight
(19.693 kDa)
References & Citations
[1]Adrian W Zuercher, et al. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019 Oct;18 (10) :102366.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Hamster Monoclonal Helios Antibody (22F6) [Alexa Fluor 647]](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
DSCR1L1, NT (RCAN2, DSCR1L1, ZAKI4, Calcipressin-2, Down syndrome candidate region 1-like 1, Myocyte-enriched calcineurin-interacting protein 2, Regulator of calcineurin 2, Thyroid hormone-responsive protein ZAKI-4) (MaxLight 550) discontinued